Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial.
Lancet Diabetes EndocrinolAug 10, 2026 (epub)
Lixin Guo, Xiaolei Bao, Kuo-Chin Huang et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 3b randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of once-weekly semaglutide 2.4 mg in Chinese adults with overweight or obesity. Among 242 participants, semaglutide led to a bodyweight reduction of -12.1% compared to -2.2% for placebo, with 80.5% achieving at least a 5% reduction versus 24.4% in the placebo group.
Key findings
- Semaglutide 2.4 mg resulted in a bodyweight reduction of -12.1% compared to -2.2% for placebo.
- 80.5% of participants on semaglutide achieved at least a 5% bodyweight reduction versus 24.4% on placebo.
- Adverse events occurred in 87.6% of the semaglutide group compared to 75.3% in the placebo group.
- Gastrointestinal disorders were the most common adverse events reported.
Why it matters
The findings highlight the effectiveness of semaglutide in promoting significant weight loss in adults with overweight or obesity, which is crucial for managing related comorbidities and improving overall health outcomes.